Fuda Cancer Hospital
Lung cancer stage 4 treatment cost in China typically includes essential diagnostics like a CT of the chest, which runs from $300 to $600. Primary medical interventions such as chemotherapy for breast cancer cost $14,800 to $31,000, while stereotaxic radiosurgery ranges from $8,500 to $15,800. Total expenses depend on drug origin, hospital tier, and systemic therapy needs. International patients often save approximately 50-70% compared to the US. Top treatment hubs include Guangzhou, Shanghai, and Beijing.
Typical Lung Cancer Stage 4 Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients benefit from minimally invasive alternatives to traditional systemic therapy. Fuda Cancer Hospital specializes in cryosurgery and NanoKnife for complex cases. These specialized protocols have served over 30,000 international patients. JCI-accredited facilities in Guangzhou provide high-value care for late-stage diagnoses. For precision radiation, Xiamen Humanity Hospital offers expert IMRT and SBRT under State Council recognized specialists. Professional coordination of thermal ablation and interventional skills ensures targeted disease management.
| China | Turkey | Austria | |
| Stereotaxic radiosurgery | from $8,500 | from $4,500 | from $17,000 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Pneumonectomy | from $24,000 | from $22,000 | from $50,000 |
| Lung cancer surgery | from $24,500 | from $9,000 | from $42,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
China offers advanced stage 4 lung cancer therapies including mutation-specific tyrosine kinase inhibitors and homegrown immunotherapies. Patients access next-generation drugs like Sunvozertinib for EGFR mutations and specialized interventions like NanoKnife or cryosurgery. JCI-accredited facilities in Guangzhou and Xiamen provide these high-tech protocols.
Bookimed Expert Insight: China's oncology landscape excels in combining interventional radiology with systemic drugs. Data shows clinics like Fuda Cancer Hospital serve over 30,000 patients using `3C` therapy. This combines cryosurgery, cancer microvascular intervention, and combined immunotherapy. While many countries focus solely on drugs, Chinese protocols often integrate physical tumor destruction for advanced cases.
Patient Consensus: Patients emphasize the need for broad genomic testing to match mutations with the right drug. Many note that outcomes improve significantly when seeking care at major thoracic oncology centers in cities like Guangzhou.
Leading Chinese hospitals for advanced-stage lung cancer include JCI-accredited hubs and specialized oncology centers in Guangzhou and Xiamen. These facilities focus on molecular profiling, cryosurgery, and microwave ablation. They provide alternatives for patients who cannot tolerate traditional systemic chemotherapy or standard surgery.
Bookimed Expert Insight: While many seek big-name public centers, specialized private hospitals in Guangzhou often provide faster access to interventional treatments. Dr. Liuying at Jinshazhou Hospital specifically contributed to national expert consensus on lung tumor ablation. These specialists focus on local tumor destruction when systemic resistance develops after initial targeted therapies.
Patient Consensus: Patients emphasize finding centers that perform rapid molecular testing and immediate biopsy reviews. Many note that traveling to major cities for initial staging is crucial to confirm genetic mutations correctly.
International patients can legally join clinical trials for lung cancer in China. Most opportunities exist within Multi-Regional Clinical Trials (MRCTs) or specific protocols without ethnic restrictions. Participation requires meeting strict biomarker profiles. Patients must also manage complex Chinese-language legal documentation and long-term residency visas.
Bookimed Expert Insight: Clinical trial enrollment is distinct from private-pay treatment at JCI-accredited centers. Clinicians like Dr. Liuying at Jinshazhou Hospital participate in provincial research projects. However, these academic studies may have stricter age limits than Western trials. Choose high-volume centers like Fuda Cancer Hospital, which has treated patients from 100+ countries, to ensure better logistical support.
Patient Consensus: Patients note trial screening takes time while Stage 4 cancer progresses fast. They emphasize getting full biomarker testing before traveling and having a standard treatment backup plan.
Traditional Chinese Medicine (TCM) serves as a supportive therapy for stage 4 lung cancer. It integrates with Western protocols like chemotherapy and immunotherapy. The approach aims to reduce treatment toxicity. Specialists focus on boosting immunity and protecting organ function during advanced oncology care.
Bookimed Expert Insight: Clinical integration in China often features specialized leadership. At the Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Dr. Liuying leads an oncology ward while holding credentials in both Chinese medicine and advanced thermal ablation. This dual expertise allows for precise timing of TCM therapies to support interventions like microwave or cryoablation without compromising the primary cancer treatment.
Patient Consensus: Patients note that TCM is highly effective for regaining appetite and managing the heavy exhaustion between chemotherapy cycles. Most emphasize that sharing all herbal ingredients with their primary oncologist is vital to avoid drug interactions.
Fitness for travel to China depends on respiratory stability and official oncology clearance. Long-haul flights pose risks like hypoxia and deep vein thrombosis for stage 4 patients. Specialized centers in Guangzhou offer minimally invasive alternatives to chemotherapy. These facilities are Joint Commission International accredited for safety.
Bookimed Expert Insight: China's top oncology centers like Fuda Hospital treat 30,000+ international patients with specific minimally invasive technologies. Our data shows these facilities often accept late-stage cases that others may decline. They use over 10 different thermal ablation techniques to target tumors without traditional major surgery. This specialized focus on advanced stages makes them a frequent choice for palliative or complex care.
Patient Consensus: Patients emphasize the need to stabilize symptoms like pain or pleural effusions before flying. They also recommend arranging portable oxygen and ground logistics before departing.
China follows CSCO guidelines which largely mirror Western NCCN and ESMO standards for stage 4 lung cancer. Protocols prioritize biomarker-driven targeted therapy and immunotherapy. Chinese centers show higher EGFR mutation rates, directing focus toward specific tyrosine kinase inhibitors and aggressive combination regimens.
Bookimed Expert Insight: Data from top-tier facilities like Fuda Cancer Hospital shows a distinct focus on combining systemic drugs with advanced local interventions. While Western protocols often stay systemic for stage 4, Chinese specialists frequently integrate microwave ablation or cryosurgery for metastases. This aggressive local-regional approach aims to reduce tumor burden alongside standard chemotherapy or immunotherapy.
Patient Consensus: Patients note that receiving international-standard care depends on choosing major urban hospitals with broad molecular testing. They emphasize getting all mutation data in writing to ensure treatments match specific cancer subtypes.